Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent’s IGF-1R Antibody NDA Under China Review for Thyroid Eye Disease

publication date: May 21, 2024

Suzhou Innovent Biologics said its NDA for IBI311, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, was accepted for review in China to treat Thyroid Eye Disease (TED). Innovent is the first company to file an NDA in China for an anti-IGF-1R antibody aimed at TED, an autoimmune disease that causes progressive inflammation and damage to tissues around the eyes. IBI311 is a biological drug with a novel mechanism of action. Innovent expects the candidate will be approved as a first-line therapy for TED, which does not have an effective therapy currently. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital